Rocket Pharmaceuticals, Inc. · NASDAQ:RCKT

Rocket Pharmaceuticals — Investor Presentation (September 2018)

34 slides from Rocket Pharmaceuticals's investor presentation, September 2018

  1. Slide 1: September 2018

    Slide 1: September 2018

    September 2018

  2. Slide 2: Important Information

    Slide 2: Important Information

    Important Information Cautionary Statement Regarding Forward-Looking Statements Various statements in this release concerning Rocket’s future expectations, plans and prospects, including without limitation, Rocket’s expectations regarding the safety, effectiveness and timing of product candidates th

  3. Slide 3: About Rocket Pharma

    Slide 3: About Rocket Pharma

    About Rocket Pharma Multi-Platform Gene Therapy (GTx) Company Targeting Rare Diseases 1st-in-class with direct on-target mechanism of action (MOA) and clear clinical endpoints Ex-vivo Lentiviral vectors • Fanconi Anemia (FA) • Leukocyte Adhesion Deficiency-I (LAD-I) • Pyruvate Kinase Deficiency (PKD

  4. Slide 4: Leadership Team - Expertise in GTx & Rare Diseases

    Slide 4: Leadership Team - Expertise in GTx & Rare Diseases

    Leadership Team - Expertise in GTx & Rare Diseases Clinical Development Gaurav Shah, M.D. President & Chief Executive Officer Jonathan Schwartz, M.D. Kinnari Patel, Pharm.D., MBA Chief Medical Officer & Head of Chief Operating Officer & Head of Clinical Development Development Spearheaded Kymriah (C

  5. Slide 5: Pipeline

    Slide 5: Pipeline

    Pipeline Discovery Preclinical Clinical Commercial FA LAD-I PKD IMO AAV 5

  6. Slide 6: Leveraging the Full Spectrum of GTx Platforms

    Slide 6: Leveraging the Full Spectrum of GTx Platforms

    Leveraging the Full Spectrum of GTx Platforms In Vivo Ex Vivo AAV Gene Therapy Lentiviral Gene Therapy Laboratory- Remove cells & Laboratory- produced AAV isolate patient HSCs produced LV Therapeutic Therapeutic LVV AAV Gene-modify HSCs Direct intravenous Infusion of injection modified HSCs 6

  7. Slide 7: Fanconi Anemia (FA)

    Slide 7: Fanconi Anemia (FA)

    Fanconi Anemia (FA) Monogenic DNA-repair disorder FA Bone Marrow Birth Defects Platelets Skin Discoloration FANC-A Gene LAD-I Mutation  RBCs Developmental Issues Bone Marrow Failure by Age 10 Chromosomal breakage Acute Myeloid Leukemia ( risk WBCs Head and Neck Cancer1 30-50x) PKD •Current availab

  8. Slide 8: Rationale for Gene Therapy in FA: Somatic Mosaicism

    Slide 8: Rationale for Gene Therapy in FA: Somatic Mosaicism

    Rationale for Gene Therapy in FA: Somatic Mosaicism = “Natural” GTx Somatic mosaicism in FA leads to stabilization/correction of blood counts, in some cases for decades. This uncommon variant results from a reverse mutation and demonstrates that a modest number of gene-corrected hematopoietic stem c

  9. Slide 9: Gene Therapy Value Proposition: Early, Low-toxicity Intervention

    Slide 9: Gene Therapy Value Proposition: Early, Low-toxicity Intervention

    Gene Therapy Value Proposition: Early, Low-toxicity Intervention to Prevent Hematologic Failure Gene therapy in FA: • Potential to correct blood & bone marrow defect without conditioning • No/limited hospitalization or transplant-unit medical care required • No anticipated further increase in risk o

  10. Slide 10: Updated Data from Phase 1/2 Gene Therapy Trial of RP-L102 in FA

    Slide 10: Updated Data from Phase 1/2 Gene Therapy Trial of RP-L102 in FA

    Updated Data from Phase 1/2 Gene Therapy Trial of RP- L102 in Patients with Fanconi Anemia Key efficacy measurements: ● Genetic correction of bone marrow cells (engraftment): measured by peripheral blood VCN ● Functional and phenotypic correction of bone marrow cells: measured by resistance to mitom

  11. Slide 11: Bone Marrow Engraftment: Increasing Levels Confirm Survival Advantage

    Slide 11: Bone Marrow Engraftment: Increasing Levels Confirm Survival Advantage

    Bone Marrow Engraftment: Increasing Levels Confirm Survival Advantage of Gene-Corrected FA Cells First Demonstration of Engraftment Without Conditioning (in contrast to Beta-thal, SCD, etc) * 02004 (Cryo) 50.0 0.5 02002 (Cryo) (6.9x103 cCFU/Kg) % Gene marked cells 4 .0 0 .0 4 G e n e m a r k e d c e

  12. Slide 12: Functional Correction of Bone Marrow

    Slide 12: Functional Correction of Bone Marrow

    Functional Correction of Bone Marrow Progressive Phenotypic Correction of BM Cells (MMC-Resistance) Y = 1 .3 1 1 * X - 0 .7 2 8 100 80 MMC Survival (%) R = 0 .9 2 M M C r e s is ta n c e 60 10 40 20 1 Months 0 6 12 24 0 6 12 0 6 12 24 0 6 12 0 Post-GT 0 10 20 30 40 50 FA-02002 FA-02004 FA-02005 FA-

  13. Slide 13: Gene Correction of Bone Marrow Stem Cells Across Lineages

    Slide 13: Gene Correction of Bone Marrow Stem Cells Across Lineages

    Gene Correction of Bone Marrow Stem Cells: Observed Across Multiple Cell Lineages Peripheral Blood Bone Marrow T o ta l B M C D 34 CD41CD42 G ly A C D 7 1 C D 14 C D 15 CD3 C D 19 60 0 .6 80 0 .8 % G e n e m a r k e d c e lls % G e n e m a r k e d c e lls C o p ie s p e r g e n o m e C o p ie s p e

  14. Slide 14: Clonal Diversity Confirms Long-term Multi-Lineage Repopulation

    Slide 14: Clonal Diversity Confirms Long-term Multi-Lineage Repopulation

    Clonal Diversity in Peripheral Blood (PB) Cells Confirms Long-term Multi-Lineage Repopulation Potential Clonal diversity Wei Wang and Manfred Schmidt Ciemat Data Patient 2002 as of Nov 2017 14

  15. Slide 15: Safety: Lentiviral Integration Profile

    Slide 15: Safety: Lentiviral Integration Profile

    Safety: Lentiviral Integration Profile Demonstrates Preferential Integration Away from Potentially Oncogenic Transcription Start Sites 10 TSS 90 8 80 76.5% % Integration Sites % Integration Sites 70 68.7% 6 60 4 50 2 40 0 30 10-5 kb 5-0 kb 0-10 10-20 20-30 30-40 40-50 50-60 60-70 70-80 80-90 90-100

  16. Slide 16: Increases of Corrected Leukocytes Support Restoration of Bone Marrow Function

    Slide 16: Increases of Corrected Leukocytes Support Restoration of Bone Marrow Function

    Increases of Corrected Leukocytes Support Restoration of Normal Bone Marrow Function Consistent with Mosaic Phenotype Kinetics of Corrected and Uncorrected PB Leukocytes Prior to and After Gene Therapy F A -0 2 0 0 2 F A -0 2 0 0 4 F A -0 2 0 0 5 F A -0 2 0 0 6 1 0 ,0 0 0 1 0 ,0 0 0 1 0 ,0 0 0 1 0 ,

  17. Slide 17: Gene Therapy Confers a Phenotype Similar to Somatic Mosaicism

    Slide 17: Gene Therapy Confers a Phenotype Similar to Somatic Mosaicism

    Gene Therapy Confers a Phenotype Similar to Somatic Mosaicism Improvement of Chromosomal Stability in Presence of DEB * 100 02002 100 02004 Healthy Donor Healthy Donor 80 80 % Non-Aberrant Cells % Non-Aberrant Cells 60 Mosaic FA 60 Mosaic FA 40 40 20 20 Non-reverted FA Non-reverted FA 0 0 0 4 8 12 1

  18. Slide 18: Gene Therapy Stabilizes Markedly Declining Blood Counts

    Slide 18: Gene Therapy Stabilizes Markedly Declining Blood Counts

    Gene Therapy Stabilizes Markedly Declining Blood Counts 300 4 14 N e u t r o p h i l s ( x 1 0 0 0 / µ l) P l a t e l e t s ( x 1 0 0 0 / µ l) 250 3 12 H b (g /d L ) 200 02002 (Cryo) 150 2 10 (1.7x104 cCFU/Kg) 100 (2.5x105 cCD34+/Kg) 50 1 8 0 0 6 -6 0 -4 0 -2 0 0 0 4 8 12 16 20 24 -6 0 -4 0 -2 0 0 0

  19. Slide 19: Promising Early Results with Transduction Enhancers

    Slide 19: Promising Early Results with Transduction Enhancers

    Promising Early Results with Transduction Enhancers Preliminary Drug Product VCN ~2.5 – 3 ; Cell Dose << 500K CD34+/kg (c o p ie s p e r g e n o m e ) 0 .0 1 5 0 .0 1 0 0 .0 0 5 in P B V C N 0 .0 0 0 0 .5 2 0 .5 2 0 .5 2 0 .5 1 .5 0 .5 2 02002 02004 02005 02006 01003 M o n th s p o st G e n e T h e

  20. Slide 20: FA: Clinical Summary & Path Forward

    Slide 20: FA: Clinical Summary & Path Forward

    FA: Clinical Summary & Path Forward • FA is a unique bone marrow disease: Somatic Mosaicism is evidence for “natural gene therapy” and provides compelling rationale for Current RP-L102 without pre-conditioning. • Early clinical results, even with a pre-optimized process, suggest RP- L102 can be a tr

  21. Slide 21: Leukocyte Adhesion Deficiency-I (LAD-I)

    Slide 21: Leukocyte Adhesion Deficiency-I (LAD-I)

    Leukocyte Adhesion Deficiency-I (LAD-I) Monogenic immunodeficiency disease FA Background: • ITGB2 gene mutation (encodes the CD18 protein) → leads to impaired CD18 expression & WBC migration → LAD-I severe and recurring infections that could be fatal • ~50% patients w/severe variant → ~2/3 mortality

  22. Slide 22: Rationale for Gene Therapy in LAD-I: CD18 Expression

    Slide 22: Rationale for Gene Therapy in LAD-I: CD18 Expression

    Rationale for Gene Therapy in LAD-I: CD18 Expression Correlative to Patient Survival Kaplan-Meier Survival Estimates by Neutrophil CD18 Expression -Patients with moderate LAD-I not receiving allogeneic HSCT- Natural history studies show the correlation between higher CD18 expression and longer patie

  23. Slide 23: LAD-I: Mouse Study Shows LAD-I Correction

    Slide 23: LAD-I: Mouse Study Shows LAD-I Correction

    LAD-I: Mouse Study Shows LAD-I Correction Primary and serially transplanted LAD mice underwent CD18 lenti GTx with different promoters Myeloablative conditioning was used Rocket chose the Chimeric cFES/CTSG (myeloid-specific ) promoter (Post-transplant PB VCN 0.4-0.9) 1o 2o Leon-Rico D, Aldea M, San

  24. Slide 24: LAD-I: Improved Process Produces VCN >~2-4

    Slide 24: LAD-I: Improved Process Produces VCN >~2-4

    LAD-I: Improved Process Produces VCN >~2-4 V C N inVCN L iq uin idLiquid C u l t u rCulture e Im p ro v e dProcess p ro c e s s No N oTransduction T r a n s d u c t iEnhancers on Improved E n h a n ce rs 4 With W it h Combination c o m b i n a t ioof n of 3 TTransduction r a n s d u c t ioEnhancers

  25. Slide 25: LAD-I Program Summary

    Slide 25: LAD-I Program Summary

    LAD-I Program Summary Ultra-rare Disease = Streamlined Regulatory Approach Potential design & clinical endpoints Target Patient Population: Severe LAD-I patients (CD18<2%), ~2/3 mortality by 2y Control: Lit review of ~300 pts. (Rocket published*) Potential Clinical Endpoints: Modest correction of CD

  26. Slide 26: Pyruvate Kinase Deficiency (PKD)

    Slide 26: Pyruvate Kinase Deficiency (PKD)

    Pyruvate Kinase Deficiency (PKD) Monogenic red blood cell disorder FA Background: • Severely affects the pediatric population • PKLR gene mutation → shortage of RBC ATP → LAD-I hemolytic anemia that can range in severity (mild to severe) • Current available treatment include transfusions & PKD splen

  27. Slide 27: PKD Program Summary

    Slide 27: PKD Program Summary

    PKD Program Summary Product/Manufacturing Optimization Positive outlook for near term optimization PoC  Target effective engraftment requirement < 50%  Optimization of vector manufacturing + transduction process  VCN now 2-4 range with TDx Enhancers Clinical Efficacy/Registration Status Registrat

  28. Slide 28: Infantile Malignant Osteopetrosis (IMO)

    Slide 28: Infantile Malignant Osteopetrosis (IMO)

    Infantile Malignant Osteopetrosis (IMO) Monogenic bone resorption disorder FA Background: • Resulting in increased bone density and impaired bone resorption LAD-I • TCIRG1 gene mutation → dysfunctional osteoclasts • Bone marrow failure, skeletal deformities, neurologic abnormalities, frequent mortal

  29. Slide 29: AAV Program (Undisclosed)

    Slide 29: AAV Program (Undisclosed)

    AAV Program (Undisclosed) FA Background: • Monogenic multi-organ, death in teens without organ Tx LAD-I • Vector with on-target MOA, tissue specific tropism • Current available treatment: Organ Tx • Prevalence US: Up to 10,000 PKD IMO AAV 29

  30. Slide 30: AAV: Activity in Mouse Model

    Slide 30: AAV: Activity in Mouse Model

    AAV: Activity in Mouse Model Wild-type KO + AAV.EGFP KO + AAV.transgene Undisclosed collaborator data on file 30

  31. Slide 31: AAV: Expression of Missing Protein in KO mice

    Slide 31: AAV: Expression of Missing Protein in KO mice

    AAV:  Expression of Missing Protein in KO mice Undisclosed AAV GTx/GAPDH Ratio 3.5 3 2.5 2 1.5 1 0.5 0 WT KO GTx Low GTx Mid GTx High Undisclosed collaborator data on file 31

  32. Slide 32: Growing IP Portfolio

    Slide 32: Growing IP Portfolio

    Growing IP Portfolio 4 in-licensed patent families for GTx products and related tech Supporting current pipeline efforts • In-licensed three pending international patent applications filed under Patent Cooperation Treaty (PCT):  FA  LAD-I  PKD • One pending PCT application:  Undisclosed AAV Effo

  33. Slide 33: World-Class Research and Manufacturing Partners

    Slide 33: World-Class Research and Manufacturing Partners

    World-Class Research and Manufacturing Partners • CIBER • El CIEMAT • Fred Hutchinson Cancer Research Center • IIS FJD • Lund University • Memorial Sloan Kettering Cancer Center • MolMed S.p.A. • Stanford Medical School 33

  34. Slide 34: Near-Term Potential Clinical Value Drivers

    Slide 34: Near-Term Potential Clinical Value Drivers

    Near-Term Potential Clinical Value Drivers 1H18 2H18 2019  FA: Updated  LAD-I: File IMPD  Up to Four Programs in Patient Data in Spain the Clinic Presented at ASGCT  AAV: First  Clinical Data expected in disclosure of up to Two Programs indication & preclinical data (Q4) 34

Source: Internet Archive copy of rocketpharma.com

More decks from Rocket Pharmaceuticals, Inc.

All 44 Rocket Pharmaceuticals decks